Squarepoint Ops LLC Has $8.96 Million Stock Position in Kiniksa Pharmaceuticals International, plc $KNSA

Squarepoint Ops LLC reduced its holdings in shares of Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) by 11.4% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 140,059 shares of the company’s stock after selling 18,034 shares during the quarter. Squarepoint Ops LLC owned approximately 0.18% of Kiniksa Pharmaceuticals International worth $8,957,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. California State Teachers Retirement System boosted its holdings in Kiniksa Pharmaceuticals International by 6,384.0% during the second quarter. California State Teachers Retirement System now owns 2,721,648 shares of the company’s stock worth $174,049,000 after purchasing an additional 2,679,673 shares during the last quarter. Qube Research & Technologies Ltd increased its stake in Kiniksa Pharmaceuticals International by 277.8% in the 2nd quarter. Qube Research & Technologies Ltd now owns 888,364 shares of the company’s stock valued at $24,581,000 after buying an additional 653,236 shares during the last quarter. Rubric Capital Management LP increased its stake in Kiniksa Pharmaceuticals International by 15.6% in the 2nd quarter. Rubric Capital Management LP now owns 3,909,806 shares of the company’s stock valued at $108,184,000 after buying an additional 526,567 shares during the last quarter. Bank of America Corp DE lifted its position in Kiniksa Pharmaceuticals International by 220.9% during the 1st quarter. Bank of America Corp DE now owns 735,940 shares of the company’s stock worth $35,436,000 after buying an additional 506,576 shares in the last quarter. Finally, Cubist Systematic Strategies LLC lifted its position in Kiniksa Pharmaceuticals International by 213.2% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 657,475 shares of the company’s stock worth $18,192,000 after buying an additional 447,536 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, CAO Michael Megna sold 4,600 shares of Kiniksa Pharmaceuticals International stock in a transaction that occurred on Thursday, September 3rd. The stock was sold at an average price of $80.30, for a total transaction of $369,380.00. Following the completion of the transaction, the chief accounting officer directly owned 29,062 shares in the company, valued at approximately $2,333,678.60. The trade was a 13.67% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director G. Bradley Cole sold 3,673 shares of the business’s stock in a transaction that occurred on Wednesday, July 29th. The stock was sold at an average price of $81.43, for a total value of $299,092.39. Following the transaction, the director directly owned 11,672 shares in the company, valued at $950,450.96. The trade was a 23.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 51.98% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on KNSA shares. Weiss Ratings cut Kiniksa Pharmaceuticals International from a “buy (b-)” rating to a “hold (c+)” rating in a report on Thursday, August 13th. Wall Street Zen lowered Kiniksa Pharmaceuticals International from a “strong-buy” rating to a “buy” rating in a report on Sunday, July 12th. The Goldman Sachs Group raised their price target on Kiniksa Pharmaceuticals International from $75.00 to $90.00 and gave the company a “buy” rating in a research note on Thursday, July 30th. Canaccord Genuity Group boosted their price target on Kiniksa Pharmaceuticals International from $64.00 to $98.00 and gave the stock a “buy” rating in a research report on Wednesday, July 29th. Finally, JPMorgan Chase & Co. upped their price objective on Kiniksa Pharmaceuticals International from $72.00 to $107.00 and gave the stock an “overweight” rating in a research note on Wednesday, July 29th. Eight research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $87.38.

Kiniksa Pharmaceuticals International Stock Performance

Shares of KNSA stock opened at $76.48 on Friday. Kiniksa Pharmaceuticals International, plc has a 52-week low of $35.20 and a 52-week high of $82.94. The stock has a market cap of $5.97 billion, a price-to-earnings ratio of 78.85 and a beta of 0.09. The firm’s 50-day moving average is $73.10 and its 200-day moving average is $58.32.

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) last posted its quarterly earnings results on Tuesday, July 28th. The company reported $0.30 EPS for the quarter, hitting analysts’ consensus estimates of $0.30. The business had revenue of $243.60 million during the quarter, compared to analysts’ expectations of $226.49 million. Kiniksa Pharmaceuticals International had a return on equity of 13.65% and a net margin of 9.59%. Sell-side analysts predict that Kiniksa Pharmaceuticals International, plc will post 1.37 EPS for the current fiscal year.

Kiniksa Pharmaceuticals International Company Profile

Kiniksa Pharmaceuticals International plc (NASDAQ: KNSA) is a biopharmaceutical company focused on discovering, developing and commercializing therapies for patients with debilitating diseases, particularly conditions involving the immune system and inflammation. The company concentrates on areas of significant unmet medical need and uses biologic medicines and other targeted approaches in its research and development programs.

Kiniksa’s principal commercial product is ARCALYST (rilonacept), an interleukin-1 inhibitor.